Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00048724
Status:
COMPLETED
Last Update Posted:
2017-04-04
First Post:
2002-11-06
Brief Title:
Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis Study P02569
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
PEG-Intron as Maintenance Therapy vs an Untreated Control Group in Adult Subjects With Compensated Cirrhosis METAVIR F4 Secondary to Chronic Hepatitis C Who Have Failed to Respond to Therapy With Any Alpha Interferon Plus Ribavirin
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of the study is to evaluate the safety and efficacy of PEG-Intron vs no treatment for the prevention of disease progression in adult subjects with compensated cirrhosis secondary to chronic hepatitis C who failed to respond to therapy with an a interferon plus ribavirin
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None